⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
HMGCR Inhibitors (Statins and Targeted Blockade)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-14 — #407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.: cross-connection with ldl-lowering-therapies: Discussion of pipeline lipid therapies overlaps with HMGCR-targeted blockade as one mechanistic lever among newer LDL-lowering approaches. (novelty: 3)
- 2026-06-03 — Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.: cross-connection with senolytics: Both converge on cholesterol biosynthesis as a driver of aging phenotypes: D+Q senolysis suppresses astrocytic cholesterol synthesis in brain aging, paralleling HMGCR blockade’s effect on senescent synovial fibroblasts in OA. (novelty: 3)
- 2026-07-13 — HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.: Mouse OA study: intra-articular AAV-mediated HMGCR inhibition reversed TNF-α-induced fibroblast-like synoviocyte senescence via an AKT1–Insig1–SCAP–HMGCR cholesterol-biosynthesis axis and reduced synovitis, cartilage loss, and pain. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.
13-jul-2026
novelty 3
per-area 3
strengthens